Stocks and Investing
Stocks and Investing
Tue, February 21, 2017
[ 09:46 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 09:45 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:46 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 07:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 04:45 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
David Nierengarten Initiated (ANAB) at Buy and Held Target at $28 on, Feb 21st, 2017
David Nierengarten of Wedbush, Initiated "AnaptysBio, Inc." (ANAB) at Buy and Held Target at $28 on, Feb 21st, 2017.
David, nor any peers, have made any analyst calls on ANAB in the last 4 months.
Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30
Contributing Sources